Abstract
A germline alteration in the PTEN gene causes a spectrum of disorders conceptualized as PTEN hamartoma tumor syndrome (PHTS), which show high risk of tumor development and a highly variable and complex phenotype. The diagnosis of PHTS is established in a proband by identification of a heterozygous germline PTEN pathogenic variant on molecular genetic testing. In this study, to understand more PTEN-associated clinical phenotype and PHTS in a Japanese population, we extracted 128 germline PTEN rare variants from 113,535 adult Japanese registered in Biobank Japan (BBJ), and categorized 29 pathogenic/likely pathogenic variants in 30 individuals (0.0264%) with ClinVar classifications and ACMG/AMP guideline for PTEN. We examined case-control association in 75,238 patients with various types of cancer and 38,297 non-cancer controls, and identified that PTEN pathogenic variants (PVs) were significantly associated with endometrial cancer (OR = 35.7, P = 9.73E-04) and marginally associated with female breast cancer (OR = 19.5, P = 3.92E-03), especially at young onset and with multiple cancers. We observed that among the 127 disease phenotypes the PTEN PV carriers had uterine fibroid, goiter, ovarian cyst, and epilepsy, which is consistent with PTEN-related phenotypes. We also found that weight/height were significantly higher in adult female carriers with PTEN PV (P = 3.1E-04 and P = 0.0014, respectively), which is consistent with overgrowth syndrome of PHTS. Our results indicate the phenotypical features associated with PTEN PVs in a Japanese population, especially female, and can contribute to the screening for PTEN variants and its associated several phenotypes.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1
Fig. 2
Fig. 3
References
Pezzolesi MG, Zbuk KM, Waite KA, Eng C. Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Hum Mol Genet. 2007;16:1058–71.
ArticleCASPubMedGoogle Scholar
Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–50.
ArticleCASPubMedPubMed CentralGoogle Scholar
Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet. 2002;70:829–44.
ArticleCASPubMedPubMed CentralGoogle Scholar
Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations. Annu Rev Med. 2020;71:103–16.
ArticleCASPubMedGoogle Scholar
Yehia L, Eng C. 65 years of the double helix: one gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine. Endocr Relat Cancer. 2018;25:T121–40.
ArticleCASPubMedGoogle Scholar
Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet. 2011;88:42–56.
ArticleCASPubMedPubMed CentralGoogle Scholar
Cummings S, Alfonso A, Hughes E, Kucera M, Mabey B, Singh N, et al. Cancer risk associated with PTEN pathogenic variants identified using multigene hereditary cancer panel testing. JCO Precis Oncol. 2023;7:e2200415.
Hendricks LAJ, Hoogerbrugge N, Venselaar H, Aretz S, Spier I, Legius E, et al. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort. Eur J Med Genet. 2022;65:104632.
ArticleCASPubMedGoogle Scholar
Trost B, Thiruvahindrapuram B, Chan AJS, Engchuan W, Higginbotham EJ, Howe JL, et al. Genomic architecture of autism from comprehensive whole-genome sequence annotation. Cell. 2022;185:4409–27.e18.
ArticleCASPubMedPubMed CentralGoogle Scholar
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980–5.
ArticleCASPubMedGoogle Scholar
Mester JL, Ghosh R, Pesaran T, Huether R, Karam R, Hruska KS, et al. Gene-specific criteria for PTEN variant curation: recommendations from the ClinGen PTEN Expert Panel. Hum Mutat. 2018;39:1581–92.
ArticlePubMedPubMed CentralGoogle Scholar
Okawa Y, Iwasaki Y, Johnson TA, Ebata N, Inai C, Endo M, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2023;78:333–42.
ArticleCASPubMedGoogle Scholar
Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018;9:4083.
ArticlePubMedPubMed CentralGoogle Scholar
Fujita M, Liu X, Iwasaki Y, Terao C, Mizukami K, Kawakami E, et al. Population-based screening for hereditary colorectal cancer variants in Japan. Clin Gastroenterol Hepatol. 2022;20:2132–41.e9.
ArticleCASPubMedGoogle Scholar
Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N. Engl J Med. 2023;388:1181–90.
ArticleCASPubMedGoogle Scholar
Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, et al. Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 common diseases. J Epidemiol. 2017;27:S9–s21.
ArticlePubMedPubMed CentralGoogle Scholar
Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, et al. Overview of the BioBank Japan project: study design and profile. J Epidemiol. 2017;27:S2–8.
ArticlePubMedPubMed CentralGoogle Scholar
Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123:1721–30.
ArticleCASPubMedGoogle Scholar
Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 2024;625:92–100.
ArticleCASPubMedGoogle Scholar
Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6:80–92.
ArticleCASPubMedPubMed CentralGoogle Scholar
Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535–48.e24.
ArticleCASPubMedGoogle Scholar
Steinhaus R, Proft S, Schuelke M, Cooper DN, Schwarz JM, Seelow D. MutationTaster2021. Nucleic Acids Res. 2021;49:W446–51.
ArticleCASPubMedPubMed CentralGoogle Scholar
Hess M, Keul F, Goesele M, Hamacher K. Addressing inaccuracies in BLOSUM computation improves homology search performance. BMC Bioinforma. 2016;17:189.
ArticleGoogle Scholar
Mighell TL, Evans-Dutson S, O’Roak BJ. A saturation mutagenesis approach to understanding PTEN Lipid phosphatase activity and genotype-phenotype relationships. Am J Hum Genet. 2018;102:943–55.
ArticleCASPubMedPubMed CentralGoogle Scholar
Matreyek KA, Stephany JJ, Ahler E, Fowler DM. Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers. Genome Med. 2021;13:165.
ArticleCASPubMedPubMed CentralGoogle Scholar
Matreyek KA, Starita LM, Stephany JJ, Martin B, Chiasson MA, Gray VE, et al. Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet. 2018;50:874–82.
ArticleCASPubMedPubMed CentralGoogle Scholar
Ou J, Zhu LJ. trackViewer: a Bioconductor package for interactive and integrative visualization of multi-omics data. Nat Methods. 2019;16:453–4.
ArticleCASPubMedGoogle Scholar
Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.
CASPubMedGoogle Scholar
Plamper M, Schreiner F, Gohlke B, Kionke J, Korsch E, Kirkpatrick J, et al. Thyroid disease in children and adolescents with PTEN hamartoma tumor syndrome (PHTS). Eur J Pediatr. 2018;177:429–35.
ArticlePubMedGoogle Scholar
Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 2016;172:402–21.
ArticleCASPubMedPubMed CentralGoogle Scholar
Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014;29:324–36.
ArticleCASPubMedGoogle Scholar
Saskin A, Fulginiti V, Birch AH, Trakadis Y. Prevalence of four Mendelian disorders associated with autism in 2392 affected families. J Hum Genet. 2017;62:657–9.
ArticleCASPubMedGoogle Scholar
Serôdio M, Calvão-Pires P, Zhang D, Sá F. Epilepsy in Cowden syndrome: beyond lhermitte-duclos disease. Acta Neurol Belg. 2023;123:2035–7.
ArticlePubMedGoogle Scholar
Plamper M, Gohlke B, Schreiner F, Woelfle J. Phenotype-driven diagnostic of PTEN Hamartoma Tumor Syndrome: macrocephaly, but neither height nor weight development, is the important trait in children. Cancers. 2019;11:975.
ArticleCASPubMedPubMed CentralGoogle Scholar
Woods NT, Baskin R, Golubeva V, Jhuraney A, De-Gregoriis G, Vaclova T, et al. Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. NPJ. Genom Med. 2016;1:16001.
CASGoogle Scholar
Download references
Acknowledgements
This work was supported by RIKEN Junior Research Associate Program (Y.K.). We thank the individuals who participated BioBank Japan. We also acknowledge the staff of the Laboratory for Genotyping Development in RIKEN, the RIKEN-IMS genome platform, and the BioBank Japan project. We are deeply grateful to the late Professor Charis Eng in Cleveland Clinic for her valuable advice on this work and her great contribution to PTEN research. Her memory continues to inspire.
Funding
This work was supported by AMED under Grant Numbers JP19kk0305010, JP20ck0106402, JP19cm0106605, and 20ck0106553.
Author information
Authors and Affiliations
Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
Yuki Kanazashi, Shota Sasagawa, Todd A. Johnson, Kazuhiro Maejima & Hidewaki Nakagawa
Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Yuki Kanazashi, Naomichi Matsumoto, Yukihide Momozawa & Hidewaki Nakagawa
Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
Yoshiaki Usui, Yusuke Iwasaki, Mikiko Endo, Mitsuyo Yamaguchi & Yukihide Momozawa
Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
Kouya Shiraishi & Takashi Kohno
Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
Teruhiko Yoshida & Kokichi Sugano
Dapartment of Genetic Medicine, Kyoundo Hospital, Sasaki Foundation, Tokyo, Japan
Kokichi Sugano
Dapartment of Molecular Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan
Yoshinori Murakami
Laboratory of Complex Trail Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
Yoichiro Kamatani
Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
Koichi Matsuda
Authors
Yuki Kanazashi
View author publications
You can also search for this author in PubMedGoogle Scholar
2. Yoshiaki Usui
View author publications
You can also search for this author in PubMedGoogle Scholar
3. Yusuke Iwasaki
View author publications
You can also search for this author in PubMedGoogle Scholar
4. Shota Sasagawa
View author publications
You can also search for this author in PubMedGoogle Scholar
5. Mikiko Endo
View author publications
You can also search for this author in PubMedGoogle Scholar
6. Mitsuyo Yamaguchi
View author publications
You can also search for this author in PubMedGoogle Scholar
7. Todd A. Johnson
View author publications
You can also search for this author in PubMedGoogle Scholar
8. Kazuhiro Maejima
View author publications
You can also search for this author in PubMedGoogle Scholar
9. Kouya Shiraishi
View author publications
You can also search for this author in PubMedGoogle Scholar
10. Takashi Kohno
View author publications
You can also search for this author in PubMedGoogle Scholar
11. Teruhiko Yoshida
View author publications
You can also search for this author in PubMedGoogle Scholar
12. Kokichi Sugano
View author publications
You can also search for this author in PubMedGoogle Scholar
13. Yoshinori Murakami
View author publications
You can also search for this author in PubMedGoogle Scholar
14. Yoichiro Kamatani
View author publications
You can also search for this author in PubMedGoogle Scholar
15. Naomichi Matsumoto
View author publications
You can also search for this author in PubMedGoogle Scholar
16. Koichi Matsuda
View author publications
You can also search for this author in PubMedGoogle Scholar
17. Yukihide Momozawa
View author publications
You can also search for this author in PubMedGoogle Scholar
18. Hidewaki Nakagawa
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
Y.M.O. and H.N. conceived and designed the study. Y.M.O., Y.M.U., Y.K., and K.M. managed the materials in B.B.J., M.E., Y.I., M.Y., and Y.M.O. produced sequence data, and Y.I. and Y.U. performed data curation. Y.K. performed data analysis and statistical tests. S.S., T.J., and Y.I. assisted the variant annotation and case-control analysis. K.S., T.K., T.Y, and K.S. assisted with the data interpretation. K.S., T.K., and Y.Mo. obtained the funding. Y.K. and H.N. wrote the initial draft of the manuscript. N.M., Y.Mo., and H.N. supervised the study. All authors reviewed this manuscript.
Corresponding authors
Correspondence to Yukihide Momozawa or Hidewaki Nakagawa.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All participants provided written informed consent. The study was approved by the ethical committees of the Institute of Medical Sciences, University of Tokyo, and RIKEN Center for Integrative Medical Sciences.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Tables S1-9
Supplementary Figures S1-6
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Kanazashi, Y., Usui, Y., Iwasaki, Y. et al. Cancer and disease profiles for PTEN pathogenic variants in Japanese population. J Hum Genet (2024). https://doi.org/10.1038/s10038-024-01311-z
Download citation
Received:01 November 2024
Revised:29 November 2024
Accepted:04 December 2024
Published:12 December 2024
DOI:https://doi.org/10.1038/s10038-024-01311-z
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative